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ABSTRACT
Background: Hepatitis B virus infection is a global health problem and vaccine-prevent-
able disease, but the duration of the effects of HBV vaccination in infants is unknown.
Objectives: The aim of this trial, which comprised children who had received 3 doses 
as part of the universal HBV immunization program and no additional doses, was to 
investigate anti-HBs titers and HBsAg status after 9 years.
Patients and Methods: We performed a descriptive, cross-sectional field research study. 
The study sample, based on sociodemographics and minimum seroprevalence, was 
analyzed based on 10.00% ± 1.50 (95% confidence interval) (1150 individuals); trial was 
realized in a total of 1279 children (623 females and 656 males). Anti-HBs titers were 
measured by micro-EIA (Dia Sorin-Italy); titers < 10 IU/mL were negative, 10-49 IU/mL 
were low-positive, and > 50 IU/mL were high-positive. For anti-HBs titers below protec-
tive levels, HBsAg was measured by micro-EIA.
Results: In approximately half of the children (48.5% in those living in semiurban areas 
and 42.3% in urban areas), antibody titers were below protective levels.
Conclusions: Mass HBV vaccination, which was implemented in Turkey in 1998, signifi-
cantly decreases HBsAg positivity in childhood. Nevertheless, it might be necessary to 
administer a booster dose after 8-9 years in children, especially those in low socioeco-
nomic areas or in whom irregular/insufficient immunization is suspected.
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1. Background
A  number  of  vaccines  have  been  used  since  1982  to 
prevent hepatitis B virus (HBV) infection. Universal HBV 
immunization  is  regarded  as  an  efficient  and  easily 
implemented method and has been recommended by 
the  World  Health  Organization  since  1997  to  be  given 
after birth in all countries. HBV immunization, which 
is currently performed in many countries, was initiated 
in 1998 in Turkey. A total of 3 doses of the HBV vaccine 
is  recommended  in  individuals  who  do  not  have  any 
immune  system  impairments;  no  booster  dose  was 
deemed to be required. However, some trials that have 
concluded  that  antibody  levels  in  infants  who  are Hepat Mon. 2011;11(6):440-444
441 The booster dose of hepatitis B for childhood Tosun S et al.
immunized at birth decrease after 6-7 years and that a 
booster dose is required (1, 2).
2. Objectives
Our  aim  was  to  measure  anti-HBs  titers  and  HBsAg 
status after 8-9 years in children who received 3 doses in 
the mass HBV immunization program, which began in 
1998 in Turkey and no additional boosters.
3. Patients and Methods
3.1. Design, sample, and data collection
Our  trial  was  a  descriptive  and  cross-sectional  field 
study.  The  study  population  was  4577  third-grade 
primary schools\ students in Manisa City Center, based 
on  2009  data  from  the  Manisa  City  Directorate  of 
National Education. Study sample of the trial- according 
to  any  sociodemographic  characteristic,  estimation 
of  minimum  level  of  the  minimum  seroprevalence 
category–was calculated on the basis of 10.00% ± 1.50% 
(95%  Confidence  Interval)  (1150  individuals);  trial  was 
realized in a total of 1279 children, 623 females and 656 
males. The subjects were selected randomly by stratified 
set  sampling  method.  Thirty-nine  primary  schools  in 
the  city  center  was  weighted  based  on  their  status  as 
a  public-private  and  urban/semi-urban  school.  Third 
grade students in the trial received an HBV vaccination 
at birth and no booster doses. A survey was completed by 
the parents, who gave informed consent for us to obtain 
blood samples from their children.
3.2. Variables
The dependent variables of the trial were HBV indicators, 
and the independent variables were date of birth, gender, 
socioeconomic  level,  health  insurance,  place  of  birth, 
maternal place of birth, and residence. 
3.3. Laboratory analysis
Per the Ethical Committee and Ministery of Health Basic 
Health  Services  General  Directorate  and  with  consent 
from the parents, schools were visited in February and 
March 2009. A 5-6-cc blood sample was obtained from 
every  student,  and  anti-HBs  titers  were  measured  by 
micro-EIA  (Dia  Sorin-Italy).  Anti-HBs  titers  <  10  IU/mL 
were regarded as negative, 10-49 IU/mL were low-positive, 
and > 50 IU/mL were high-positive. For cases with anti-
HBs titers below protective levels, HBsAg was measured 
by micro-EIA (Dia Sorin-Italy).
3.4. Data analysis
Descriptive statistics, Pearson chi square, t-test, and one-
sided variance analysis (ANOVA) were used to analyze the 
data using SPSS 10.0. 
4. Results
4.1. Sample characteristics
The number of children in the trial was 1279, comprising 
51.3% (656) boys and 48.7% (623) girls. The percentages of 
children from upper, middle, and lower socioeconomic 
levels  were  8.9%  (114),  47.7%  (610),  and  43.3%  (555), 
respectively. The immunity of children by socioeconomic 
characteristics is shown in Table 1, and their susceptibility 
to risk of hepatitis B is listed in Table 2. The immunity 
status  of  the  participants  by  socioeconomic  level  is 
shown in  Figure 1.
4.2. Hepatitis B immunity status by socioeconomic level
In  approximately  half  of  the  children  who  were 
vaccinated at birth in mass HBV immunization program, 
antibody titers were below protective levels—48.2% in the 
upper socioeconomic level, 41.3% in the middle level, and 
50.1% in the lower level. These differences were significant, 
and the best antibody levels were observed in children 
from the middle socioeconomic level (p = 0.009).
4.3. Relationships between study variables
No  relation  was  noted  between  family  income  or 
gender  and  protective  antibody  level.  A  significant 
difference  was  observed  between  children  who  were 
born in health institutes (55.3%) and elsewhere (46.9%) (p 
= 0.025 OR:1.40 95% CI:1.04-1.89). Immunity levels levels 
differened  significantly  between  the  low  and  middle-
upper socioeconomic levels (p = 0.005 OR:1.37 95% CI:1.10-
1.71).  No  correlation  was  observed  between  having  a 
hepatitis  patient/carrier  at  home,  hepatitis  history,  or 
hepatitis family history and immunity levels.
Antibody titers were below protective levels in 43.7% of 
those with health insurance and in 50.7% in those without 
it or holders of green card insurance (p = 0.017 OR:1.05 
95%  CI:1.05-1.71)  Anti-HBs  titers  were  below  protective 
levels in 48.5% of people who were living in semiurban 
areas and 42.3% in those in urban areas. 
Figure 1. Immunity Status by Socioeconomic Level in Children (%)Hepat Mon. 2011;11(6):440-444
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Demographic 
characteristic
HBsAg (+) 
No. (%)
Anti-HBs IU/mL No.(%) Arithmetic a 
Mean ± SD Statistics Total
< 10 IU/mL 10-49 IU/mL > 50 IU/mL
Socioeconomic level 
High
Middle
Low
_
1 (0.2)
1 (0.2)
55 (48.2)
252 (41.3)
278 (50.1)
11 (9.6)
78 (12.8)
73 (13.2)
48 (42.2)
279 (45.7)
203 (36.5)
1.33 ± 0.96
1.43 ± 0.93
1.26 ± 0.94
p = 0.006
f = 5.12
 _
114
610
555
Health insurance
Yes
No-Green Card
1 (0.1)
1 (0.3)
392 (43.7)
187 (50.7)
110 (12.3)
48 (13.0)
393 (43.9)
133 (36.0)
1.39 ± 0.95
1.25 ± 0.92
p = 0.020
t = 2.33
896
369
Residence
Urban
Semi urban
1 (0.2)
1 (0.1)
208 (42.1)
327 (48.2)
69 (14.0)
79 (11.6)
216 (43.7)
272 (40.1)
1.43 ± 0.91
1.29 ± 0.96
P = 0.012
t = 2.51
494
679
Place of birth
Manisa-Izmir
Other
1 (0.1)
1 (0.5)
472 (44.4)
108 (53.8)
137 (12.9)
22 (10.9)
452 (42.6)
70 (34.8)
1.37 ± 0.93
1.19 ± 0.96
p = 0.012
t = 2.52
1062
201
Place of birth of mother
Manisa-Izmir
Other
Total
   
 _
2 (0.3)
2 (0.2%)
207 (40.3)
363 (49.3)
585 (45.7%)
72 (14.0)
86 (11.7)
162 (12.7%)
235 (45.7)
285 (38.7)
530 (41.4%)
1.45 ± 0.91
1.28 ± 0.96
1.35 ± 0.94
p = 0.002
t = 3.07
_
514
736
1279
Table 1. Immunization among children according by sociodemographics a
a Analysis was performed by log10-transforming anti-HBs titers.
trials have indicated that following vaccination at birth, 
the  anti-HBs  response  decreases  over  time  and  that 
a booster dose is required. In a study in which blood 
samples were drawn from children at age 5 years who 
were given a yeast-based vaccine at birth, only 26 (12.5%) 
of 208 children had a seroprotective anti-HBs response; 
in the 7-year evaluations, no seroprotective response was 
observed in any of 36 children who were tested. When 1 
booster was administered to these children, a protective 
response with a ratio of 90% was seen in both groups. The 
trial authors concluded that in the majority of children 
who are vaccinated at birth, anti-HBs titers decline but 
that immunological memory exists, effecting a response 
very good to booster doses. They emphasized that large-
scale  trials  are  needed  to  determine  whether  booster 
doses  are  required  in  children  who  are  vaccinated  at 
birth and the timing of such boosters (12).
Similarly,  in  a  trial  in  Iran,  where  a  national  HBV 
immunization  program  was  initiated  in  1993,  of  the 
3758  children  who  were  vaccinated  in  this  program, 
19.3% had anti-HBs levels < 10 IU/mL, 51.6% was between 
10-100 IU/mL, and 29.2% was > 100 IU/mL (13). In a trial 
in Manisa in 2008, HBV seroprevalence before and after 
immunization  was  examined  among  primary  school 
students, and hepatitis B vaccine was administered to 
children before or after blood samples were drawn in 
the immunization program of the Ministery of Health. 
The  study  group  observed  that  70.7%  of  children  who 
received the booster dose were immune (No.:571) versus 
34.3% (No.:239) of children who did not (x² = 200.119, p 
= 0.000). As expected, anti-HBs titers in children who 
received reminder doses were also significantly higher 
(p = 0.000, t = 18.58) versus those who did not (14).
We  observed  that  in  children  who  were  vaccinated 
(p  =  0.037  OR:1.28  95%  CI:1.01-1.61).  The  percentage  of 
children who were born in Manisa or Izmir with anti-HBs 
titers < 10 IU/mL was 44.6% versus 54.2% for those born 
elsewhere (p = 0.012 OR:1.47 95% CI:1.08-1.98). Similarly, 
40.3% of children whose mothers were born in Manisa 
or Izmir had anti-HBs < 10 IU/mL compared with 49.7% of 
children whose mothers were born elsewhere (p = 0.001 
OR:1.46 95% CI:1.16-1.84). 
5. Discussion
Mass hepatitis B immunization has been successful in a 
number of trials (3-6), This program, which is widespread 
and being implemented in many countries, was adopted 
in  Turkey  for  the  routine  immunization  of  newborns 
and risk groups in August 1998. Certain revisions in the 
immunization  schedule  were  made,  as  indicated  in 
circulars on this issue; the latest revisions recommeded 
the  first  dose  to  be  administered  at  birth,  the  second 
dose at 1 month, and last dose 4 months after the second 
dose. In terms of protection against hepatitis B infection, 
when antiHBs titers exceed 10 mIU/mL, even if it decreases 
later, protection against hepatitis B infection continues; 
in babies who are vaccinated at birth, booster doses are 
not required for at least 5 years, and there are sufficient 
immune  memory  cells  that  effect  good  responses  to 
boosters (6-10).
The  World  Health  Organization  states  that  boosters 
are  not  required,  following  properly  administered 
hepatitis  B  vaccinations.  Recommendations  of  the 
European  Consensus  Group  on  Hepatitis  B  Immunity 
also  opine  that  no  booster  is  required  in  individuals 
with complete immunization and in those who do not 
have any immune-related problems (11). However, some Hepat Mon. 2011;11(6):440-444
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at  birth  in  2000  and  received  no  boosters,  48.2%, 
41.3%, and 50.1% of those in the high, middle, and low 
socioeconomic levels were negative (< 10 IU/mL) for anti-
HBs responses, respectively; 9.6%, 12.8%, and 13.2% had low 
anti-HBs (10-49 IU/mL) responses, respectively, and 42.2%, 
45.7%, and 36.5% had high titers, indicating that antiHBs 
titers decrease 8-9 years after mass immunization. Two 
hundred ninety of 585 children with anti-HBs titers < 
10 IU/mL were contacted again and given and 1 dose of 
HBV. One month later, all but 5 had high antiHBs titers; 
in these 5 children, 1 experienced immunosupression, 
1 was mentally retarded, and the remaining 3 had not 
been immunized since birth. These results indicate that 
primary immunization in a universal HBV vaccination 
program is favorable but that anti-HBs titers decrease to 
undetectable levels over time. A meta-analysis from Iran 
of 34 studies that comprised 9356 individuals concluded 
that  additional  studies  are  needed  to  assess  vaccine 
efficacy for longer periods, as are booster doses in various 
subgroups (15).
The lack of protective anti-HBs production, despite HBV 
vaccination,  can  result,  possibly  from  noncompliance 
with cold chain procedures; administration of vaccine 
to  an  inappropriate  area  of  the  body;  incorrect 
vaccination  procedure;  loss  of  efficacy  of  the  vaccine, 
which is especially susceptible during freezing; failure 
to administer the vaccine at birth; delay in vaccination; 
and a having an HbsAg-positive mother. In addition, the 
initial administration of HBV vaccine in Turkey varied 
with  regard  to  start  time,  which  might  have  affected 
the long-term antibody response. Thus, a booster dose 
should be given 8-9 years after universal immunization 
if a child is born in an endemic area, if the mother or any 
family member shows HBsAg positivity, if the vaccination 
history of the child is unknown, if there is any uncertainty 
with regard to the storage/administration of the vaccine, 
or  if  the  child  lives  in  a  low  socioeconomic  area.  In 
addition,  HBsAg  should  be  measured  in  all  pregnant 
women, especially those from low socioeconomic areas, 
and be recorded in their follow-up information, so that 
vaccine + HBIG can be administered to babies who are 
born to carriers and so that mothers who deliver at home 
can be identified as soon as possible to enroll the babies 
in the immunization program. 
In  conclusion,  mass  HBV  immunization,  which  was 
begun  in  1998  in  Turkey,  has  significantly  decreased 
HBsAg positivity, especially during childhood. However, 
for  children  who  are  suspected  of  having  irregular/
insufficient  immunization  or  those  who  live  in  low 
socioeconomic areas, a booster dose might be necessary 
8-9 years after primary immunization.
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